Haleon plc (HLN)vsTherapeuticsMD Inc (TXMD)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
TXMD
TherapeuticsMD Inc
$2.29
0.00%
HEALTHCARE · Cap: $26.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 394392% more annual revenue ($11.03B vs $2.80M). HLN leads profitability with a 15.1% profit margin vs 10.8%. HLN trades at a lower P/E of 20.6x. HLN earns a higher WallStSmart Score of 58/100 (C).
HLN
Buy58
out of 100
Grade: C
TXMD
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Margin of Safety
-3357.1%
Fair Value
$0.07
Current Price
$2.29
$2.22 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Reasonable price relative to book value
Revenue surging 43.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : TXMD
The strongest argument for TXMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 43.3% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : TXMD
The primary concerns for TXMD are EPS Growth, Market Cap, Return on Equity. A P/E of 229.0x leaves little room for execution misses.
Key Dynamics to Monitor
HLN profiles as a value stock while TXMD is a growth play — different risk/reward profiles.
TXMD carries more volatility with a beta of 0.54 — expect wider price swings.
TXMD is growing revenue faster at 43.3% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 39/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →TherapeuticsMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?